PAREXEL International Announces $50M Share Repurchase Agreement
PAREXEL International Corporation (Nasdaq: PRXL) today provided an update and announced the next steps with regard to the Company's share repurchase program.Tags: PAREXEL International
View ArticleClik here to view.
Why Synta Pharmaceuticals Shares Stumbled
What: Shares of Synta Pharmaceuticals (NASDAQ: SNTA ) , a biopharmaceutical company focused on developing drugs to treat cancer and other inflammatory diseases, sank as much as 17% after reporting its...
View ArticleTetraphase Pharmaceuticals Prescribing An IPO
The Initial Public OfferingTetraphase Pharmaceuticals (TTPH) is pricing 6.8 million shares of its common stock in an initial public offering managed primarily by Barclays and BMO Capital Markets....
View ArticleClik here to view.
Tetraphase Pharmaceuticals Prices IPO
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced the pricing of its initial public offering of 10,714,286 shares of common stock at a price to the public of...
View ArticleEnanta Pharmaceuticals Prices 4M Shares Offering
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious...
View ArticleClik here to view.
Inspiration Biopharmaceuticals and Ipsen Closes sale of OBI-1 To Baxter...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Inspiration Biopharmaceuticals, Inc. (Inspiration) and Ipsen (Euronext: IPN; ADR: IPSEY) announced the closing of the sale of its lead hemophilia program, OBI-1, to...
View ArticleH&Q Healthcare Investors Announces Renewal of Share Repurchase
BOSTON--(BUSINESS WIRE)--H&Q Healthcare Investors (NYSE: HQH) announced that the Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows...
View ArticleH&Q Life Sciences Investors Announces Renewal of Share Repurchase
BOSTON--(BUSINESS WIRE)--H&Q Life Sciences Investors (NYSE: HQL) announced that the Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program...
View ArticleClik here to view.
Biovista and DART Therapeutics Enter Into Drug Repositioning Collaboration...
Cambridge, Mass. and Charlottesville, Va.—March 26, 2013—DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy (DMD), and...
View ArticleClik here to view.
T2 Biosystems Completes $40 Million Series E Financing
T2 Biosystems announced the completion of a $40 million financing to support the clinical programs and commercialization of T2Candida,
View ArticleClik here to view.
NeuroPhage Pharmaceuticals Raises $3.7 Million
NeuroPhage Pharmaceuticals Inc. has raised $3.7 million via sales of shares to 31 investors, according to an SEC filing. Last year, the Cambridge-based Tags: NeuroPhage Pharmaceuticals
View ArticleTokai Pharmaceuticals Appoints Jodie Morrison as Chief Executive Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, announced the appointment of Jodie Morrison to the...
View ArticleClik here to view.
Bain Capital, Thomas H. Lee Partners in Race to Acquire Carestream Health
A bidding war is brewing among three top private equity firms – Bain Capital LLC, Carlyle Group LP and Thomas H. Lee Partners LP – over Carestream Health Inc., a medical imaging systems provider,...
View ArticleClik here to view.
Precision for Medicine Raises $150 Million
Precision for Medicine, Inc., formed in 2012 to support next-generation approaches to drug development and commercialization, today announced that it has secured $150 million
View ArticleClik here to view.
Tetraphase Pharma - Update on IPO
Tetraphase Pharma (TTPH): This is another new antibiotic drug developer working to solve the problem of increasing resistance to existing antibiotic therapies. Tetraphase has a lead drug candidate...
View ArticleClik here to view.
Syros Pharmaceuticals Lands $30M Series A Financing
Syros Pharmaceuticals, a newly launched company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases, Tags: Syros Pharmaceuticals
View ArticleClik here to view.
Royalty Pharma Announces Firm Offer to Acquire Elan
Echo Pharma Acquisition Limited announced, pursuant to Rule 2.5 of the Irish Takeover Rules, the terms of a firm, all cash offer for the entire issued and to be issued share capital of Elan...
View ArticleInfinity Announces Closing of Secondary Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the closing of an underwritten public offering of its common stock, at a price of $40.00 per share, by...
View ArticleClik here to view.
Mass Bay Spine & Sport Physical Therapy Promotes Kathleen Young To Office...
Mass Bay Spine & Sport Physical Therapy (MBSSPT) of Marshfield has recently promoted Kathleen Young, a Marshfield resident, to the position of Office Manager.Tags: Kathleen Young
View ArticleClik here to view.
MPM Capital-backed Epizyme Files for $69 Million IPO
Epizyme, which develops cancer therapeutics, plans to raise up to $69 million in an initial public offering of shares, according to an SEC filing.
View Article
